Financials

v2.4.0.8
Consolidated Balance Sheets (USD $)
Mar. 31, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 13,391,697 $ 10,048,466
Short-term investments 280,213 305,538
Accounts receivable 414,857 458,391
Other current assets 377,288 344,386
Total current assets 14,464,055 11,156,781
Equipment, net 384,366 457,912
Restricted cash 2,679,559 2,921,724
Other long-term assets 137,057 159,224
Total assets 17,665,037 14,695,641
Current liabilities:    
Accounts payable 489,441 794,397
Accrued expenses 2,972,849 2,445,446
Deferred revenue 1,086,720 1,069,438
Accrued warrant liability 1,436,845 1,241,311
Current portion of notes payable 892,828 351,527
Current portion of capital lease obligation 71,350 83,634
Total current liabilities 6,950,033 5,985,753
Noncurrent portion of capital lease obligation   7,522
Long-term debt 6,725,799 7,121,388
Commitments and contingencies      
Total liabilities 13,675,832 13,114,663
Stockholders' equity:    
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively      
Common stock, $.005 par value; 160,000,000 shares authorized, 50,942,798 and 45,182,114 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively 254,714 225,911
Additional paid-in capital 130,080,558 125,508,471
Accumulated other comprehensive income 117,324 307,339
Accumulated deficit (137,150,038) (135,564,666)
Total Cleveland BioLabs, Inc. stockholders' deficit (6,697,442) (9,522,945)
Noncontrolling interest in stockholders' equity 10,686,647 11,103,923
Total stockholders' equity 3,989,205 1,580,978
Total liabilities and stockholders' equity $ 17,665,037 $ 14,695,641
v2.4.0.8
Consolidated Statements of Operations (USD $)
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Revenues:    
Grants and contracts $ 1,334,254 $ 1,367,472
Operating expenses:    
Research and development 2,439,773 5,331,615
General and administrative 2,413,543 3,483,372
Total operating expenses 4,853,316 8,814,987
Loss from operations (3,519,062) (7,447,515)
Other income (expense):    
Interest and other income (expense) (317,922) 79,956
Foreign exchange gain (loss) (151,771) 28,134
Change in value of warrant liability 2,087,558 (3,447,723)
Total other income (expense) 1,617,865 (3,339,633)
Net loss (1,901,197) (10,787,148)
Net loss attributable to noncontrolling interests 315,825 1,022,825
Net loss attributable to Cleveland BioLabs, Inc. $ (1,585,372) $ (9,764,323)
Net loss available to common stockholders per share of common stock, basic and diluted $ (0.03) $ (0.22)
Weighted average number of shares used in calculating net loss per share, basic and diluted 49,968,131 44,826,576
v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Cash flows from operating activities:    
Net loss $ (1,901,197) $ (10,787,148)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 57,811 94,927
Amortization 91,929  
Loss on equipment disposal 24,685  
Noncash compensation 48,416 635,005
Warrant issuance costs 171,116  
Change in value of warrant liability (2,087,558) 3,447,723
Changes in operating assets and liabilities:    
Accounts receivable 41,901 (435,284)
Other current assets (54,818) (74,125)
Other long-term assets 9,847 (22,619)
Accounts payable (273,086) (286,377)
Deferred revenue 108,127 (219,280)
Accrued expenses 929,518 643,876
Net cash used in operating activities (2,833,309) (7,003,302)
Cash flows from investing activities:    
Sale of short-term investments   1,315,175
Purchase of equipment (10,805) (20,054)
Net cash provided by (used in) investing activities (10,805) 1,295,121
Cash flows from financing activities:    
Issuance of common stock, net of offering costs 6,355,001  
Repayment of capital lease obligation (19,806) (16,974)
Net cash provided by (used in) financing activities 6,335,195 (16,974)
Effect of exchange rate change on cash and equivalents (147,850) (157,915)
Increase (decrease) in cash and cash equivalents 3,343,231 (5,883,070)
Cash and cash equivalents at beginning of period 10,048,466 25,652,083
Cash and cash equivalents at end of period 13,391,697 19,769,013
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest 159,780 5,861
Supplemental schedule of noncash financing activities:    
Noncash financing costs on common stock offering 50,505  
Noncash warrant issuance costs $ 15,993  
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue